SALT LAKE CITY, March 06, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the full year ended December 31, 2016.
"During the quarter and subsequent period, we have made significant progress on the development of both LPCN 1021 and LPCN 1107," said Dr. Mahesh Patel, Chairman, President and CEO of Lipocine. "We currently expect this progress to continue in the near term, with top line results from our on-going LPCN 1021 studies and a SPA filing for LPCN 1107, both expected before mid-2017."
Full Year 2016 Financial Results
Lipocine reported a net loss of $19.0 million, or $1.04 per diluted share, for the full year of 2016, compared with a net loss of $18.2 million, or $1.11 per diluted share, for the full year of 2015.
For the full year of 2016, research and development expenses were $8.1 million, compared with $12.6 million for the full year of 2015. The change was primarily due to decreased contract research organization and consultant costs of $3.8 million. In addition, during the year ended December 31, 2015, we incurred a $2.3 million fee to file our NDA for LPCN 1021 with the FDA. These decreases in 2016 were offset by an increase in validation and commercial batch manufacturing costs for LPCN 1021 in 2016 of $1.7 million
For the full year of 2016, general and administrative expenses were $10.4 million, compared with $5.8 million for the full year of 2015. The change was primarily due an increase of $2.0 million in personnel costs due primarily to increased salaries and stock-based compensation related to a higher average headcount in 2016, an increase of $1.2 million for pre-commercialization marketing and sales activities related to LPCN 1021, and an increase of $750,000 in legal costs for class action defense and patent interference.
The full year of 2016 also included $0.7 million of restructuring costs.
As of December 31, 2016, Lipocine had cash, cash equivalents and marketable investment securities of $26.8 million, compared with cash and cash equivalents of $44.8 million as of December 31, 2015.
Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes three development programs LPCN 1021, LPCN 1111 and LPCN 1107. LPCN 1021, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. LPCN 1021 was well tolerated and met the primary efficacy end-point in Phase 3 testing, which utilized 24-hour pharmacokinetic data for dose adjustments, and is currently being studied in two additional Phase 3 clinical trials. LPCN 1111, a novel oral prodrug of testosterone, originated with and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and is currently in Phase 2 testing. LPCN 1107, the potentially first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth, has been granted orphan drug designation by the FDA. An End of Phase 2 meeting with the FDA has been completed. For more information, please visit www.lipocine.com.
This release contains "forward looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding Lipocine's product candidates and related clinical trials and the FDA review process relating to its product candidates, plans related to clinical trials, the possible outcome and timing of such clinical trials, the expected timing of clinical trial results or any related FDA review process, the path to approvability by the FDA of Lipocine's development programs, the potential uses and benefits of our product candidates, and our product development efforts. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that the FDA will not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, advance regulatory developments and requirements, risks related to the FDA approval process, the receipt of regulatory approvals, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.
|LIPOCINE INC. AND SUBSIDIARIES|
|Consolidated Statements of Operations and Comprehensive Loss|
|Years Ending December 31, 2016, 2015 and 2014|
|Research and development||$||8,076,053||$||12,580,245||$||15,479,446|
|General and administrative||10,382,146||5,801,823||5,001,368|
|Total operating expenses||19,186,834||18,382,068||20,480,814|
|Other income, net||216,078||173,890||108,338|
|Loss before income tax expense||(18,970,756||)||(18,208,178||)||(20,372,476||)|
|Income tax expense||(752||)||(200||)||(200||)|
|Basic loss per share attributable to common stock||$||(1.04||)||$||(1.11||)||$||(1.60||)|
|Weighted average common shares outstanding,||18,258,149||16,470,814||12,766,295|
|Diluted loss per share attributable to common stock||$||(1.04||)||$||(1.11||)||$||(1.60||)|
|Weighted average common shares outstanding, diluted||18,258,149||16,470,814||12,766,295|
|Unrealized net gain (loss) on available-for-sale securities||24,407||(32,900||)||-|
|LIPOCINE INC. AND SUBSIDIARIES|
|Consolidated Balance Sheets|
|December 31, 2016 and 2015|
|Cash and cash equivalents||$||5,560,716||$||20,007,659|
|Marketable investment securities||21,279,570||24,375,168|
|Accrued interest income||38,943||144,536|
|Prepaid and other current assets||329,548||350,160|
|Total current assets||27,208,777||44,877,523|
|Property and equipment, net of accumulated depreciation|
|of $1,092,710 and $1,060,750, respectively||103,440||75,750|
|Long-term marketable investment securities||-||400,252|
|Liabilities and Stockholders' Equity|
|Total current liabilities||1,326,169||3,391,861|
|Commitments and contingencies|
|Preferred stock, par value $0.0001 per share, 10,000,000|
|shares authorized; zero issued and outstanding||-||-|
|Common stock, par value $0.0001 per share, 100,000,000|
|shares authorized; 18,462,325 and 18,250,456|
|issued and 18,456,615 and 18,244,746 outstanding||1,846||1,825|
|Additional paid-in capital||131,481,123||128,502,659|
|Treasury stock at cost, 5,710 shares||(40,712||)||(40,712||)|
|Accumulated other comprehensive loss||(8,493||)||(32,900||)|
|Total stockholders' equity||26,016,801||41,985,417|
|Total liabilities and stockholders' equity||$||27,342,970||$||45,377,278|
CONTACT: Morgan Brown Executive Vice President & Chief Financial Officer Phone: (801) 994-7383 email@example.com Investors: John Woolford Phone: (443) 213-0506 firstname.lastname@example.org